Krystal Biotech reported quarterly EPS of $1.83, beating the $1.45 Zacks Consensus Estimate by $0.38 and improving from $1.20 a year ago. The result is a solid earnings beat with year-over-year growth, pointing to stronger underlying fundamentals. This is positive for the stock but likely a company-specific move rather than sector-wide news.
Krystal Biotech reported quarterly EPS of $1.83, beating the $1.45 Zacks Consensus Estimate by $0.38 and improving from $1.20 a year ago. The result is a solid earnings beat with year-over-year growth, pointing to stronger underlying fundamentals. This is positive for the stock but likely a company-specific move rather than sector-wide news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.36
Ticker Sentiment
